New research uncovers the mystery of cancer immunotherapy resistance July 27, 2017 Source: Xinhua News Agency Cancer immunotherapy is a therapy against cancer cells by means of the autoimmune system, and has broad application prospects. However, the problem of cancer drug resistance has been difficult to understand. Swiss researchers have recently discovered that an epigenetic regulatory protein plays a key role in the development of drug resistance in cancer cells, and inhibition of this protein can help solve cancer drug resistance problems. There are special markers on the surface of cancer cells that allow immune cells to detect and respond to cancer cells. However, "smart" cancer cells reduce these markers that can be found by immune cells, while producing special molecules to suppress the immune response. As a result, immune cells can hardly find cancer cells, and immunotherapy fails. What makes cancer cells so "smart"? Researchers at the University Hospital in Zurich have found that an epigenetic regulatory protein called Ezh2 plays a key role. Animal experiments have shown that when immunosuppressive agents such as immunological checkpoint inhibitors or interleukin-2 are used to treat melanoma, the tumors will initially shrink, but over time, cancer cells will produce a large amount of Ezh2, causing the cancer cells to "mark" less. The immune response is inhibited and the cancer cells proliferate again without restriction. After the researchers used drugs to inhibit the activity of Ezh2, the effect of immunotherapy improved and the tumors shrank significantly. Researchers say the latest research reveals the mechanisms by which cancer cells develop resistance in immunotherapy, helping to develop more effective anticancer drugs in the future. Related research is published in the new issue of the American Cell Report. (Reporter Liu Qu) Spindle Analyzer,Cnc Spindle Analysis,Spindle Analyzer For Machine Tool,Api Swivel Check Automated Precision Inc. , https://www.apiasean.com